OR WAIT null SECS
Novo Nordisk has announced plans to invest more than 17bn Danish kroner (US$2bn) in the construction of three new manufacturing facilities, as well as expanding one existing facility at its production site in Kalundborg, Denmark.
The investment will establish additional capacity across the entire global value chain from manufacturing of active pharmaceutical ingredients (API) to assembly and packaging, with the vast majority being invested in API capacity. These expansions will provide capacity for the production of Novo Nordisk’s current and future oral and injectable products. The new facilities will be automated and include state-of-the-art production technologies.
“Kalundborg is currently the cornerstone in our production of API and the expansion of the manufacturing capacity is important to meeting the future demands of patients. The investment announced today emphasises our continued commitment to Denmark and Kalundborg being at the heart of our global manufacturing setup”, said Henrik Wulff, EVP, Product Supply, Quality & IT, Novo Nordisk.
The investment projects are expected to be finalized in 2027 and will create around 400 new jobs. More than 2,500 external staff will be engaged in the building phase.